natgillin/translations-raw huggingface dataset:
The number of the reactors to be connected is not limited. 
05.12.2012. Broj objave europskog patenta:
providing an extraction well comprising: a first anchoring pipe fixed to a seabed or other geological formation where an underground reservoir to be exploited lies, the first anchoring pipe arranged close to a surface of the seabed or the other geological formation; 
prvu sidrenu cijev (30), pričvršćenu na morsko dno ili koju drugu geološku formaciju, gdje leži podzemni spremnik koji će se eksploatirati, gdje se prva sidrena cijev (30) nalazi blizu površine morskog dna ili koja druge geološke formacije u pitanju;
at least one exit interface conveyor for exits of loads out of the system, 
• najmanje jednu ulaznu transportnu traku (70R, 80R) za robu koja ulazi u sustav;
(c2) an antigen-binding site comprising an L chain CDR1, 2, and 3 amino acid sequences of SEQ ID NOs: 141, 142, and 143 (L chain CDR of L45), respectively; (c3) an antigen-binding site comprising an L chain CDR1, 2, and 3 amino acid sequences of SEQ ID NOs: 144, 145, and 146 (L chain CDR of L248), respectively; 
(c2) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 213 od SEQID NO: 141, 142 odnosno 143 (L-lanac CDR- područja od L45); (c3) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 213 od SEQ ID NO: 144, 145 odnosno 146 (L-lanac CDR- područja od L248); HR P20180421 T1
The pharmaceutical composition of any of claims 1-3 wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 7.5 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 7,5 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCI 1 63 mM FCI, pH 1,21 na 37%.
The interaction can be for example an extraction, brewing, dissolution, mixing etc. process. 
Interakcija može biti postupak kao što je, na primjer, ekstrakcija, kuhanje, otapanje, miješanje i tako dalje.
A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation within nucleotides 170 to 235 (-784 to -719) of Seq ID No. 1 for high expression under methanol induced conditions. 
Promotor alkoholne oksidaze | mutantne Pichia pastoris (AOX1), naznačen time, da je to promotor divljeg tipa Pichia pastoris AOX1 (SEQ ID No.1) koji sadrži najmanje jednu mutaciju unutar nukleotida 170 do 235 (-784 do - 719) od SEQ ID No.1 za visoku ekspresiju pod uvjetima induciranog metanola.
The method of any of Claims 1 to 5, wherein the aqueous acetate or glutamate buffered G-CSF composition provided in step (a) has a volume of from 0.1 ml to 8 l, preferably of from 5 ml to 4 l, and more preferably of from 100 ml to 1.5 l. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time, da vodeni acetat ili glutamat puferiranog G-CSF- sastava, koji je pribavljen u koraku (a), ima volumen od 100 ml do 4 [, 1 još bolje od 100 ml do 1,5 L
2.500 Pharmacological activity The compositions above are specific examples of preferred embodiments of the invention, wherein an M3 antagonist of Formula I is combined with a B2-agonist. 
Gornji su pripravci specifični primjeri poželjnih utjelovljenja sukladno predmetnom izumu, kod kojih se M3 antagonist sukladno predmetnom izumu kombinira s kortikosteroidom.
The compound, the pharmaceutically acceptable salt, or the solvate thereof, for use in treating and/or preventing influenza infectious disease according to claim 1, wherein R1 is hydrogen, halogen, hydroxy, carboxy, lower alkyl optionally substituted by substituent group A, lower alkenyl optionally substituted by substituent group A, lower alkyloxy optionally substituted by substituent group A, lower alkylcarbonyl optionally substituted by substituent group A, lower alkyloxycarbonyl optionally substituted by substituent group A, heterocyclic group optionally substituted by substituent group A, Z-N(RX1)(RX2), 
Spoj, njegova farmaceutski prihvatljiva sol, ili njegov solvat, za uporabu u liječenju i/ili prevenciji infektivne bolesti gripe prema zahtjevu 1, naznačen time, da R' je vodik, halogen, hidroksi, karboksi, niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkiloksi prema potrebi supstituiran sa supstituentskom skupinom A, niži alkilkarbonil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkiloksikarbonil prema potrebi supstituiran sa HR P20180885 T1 supstituentskom skupinom A, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom A,
The method according to claim 6, wherein the L1 signaling information further have PLP PAYLOAD TYPE information which indicates the type of payload data carried by the PLP 
Metoda u skladu s patentnim zahtjevom 6, pri čemu informacija signaliziranja L1 nadalje ima informaciju vrste podataka PLP polja koja ukazuje vrstu podataka polja koje prenosi PLP.
If the pKa at 25° C. is from 0 to 2.5, the acid is preferably selected from H2SO3, HSO4−, H3PO4, oxalic acid or mixtures thereof. 
Postupak prema zahtjevu 4, pri čemu kiselina ima pK, pri 25*C od 0 do 2.5, te je preporučeno H2SO;, HSOy, H;PO., oksalna kiselina, ili njihova smjesa.
The angiotensin converting enzyme inhibitors belong to the class of drugs that partially lower blood glucose levels as well as lowering blood pressure by inhibiting angiotensin converting enzymes. 
Inhibitori angiotenzin-konvertaza enzima pripadaju skupini lijekova koji djelomično snižavaju nivoe šećera u krvi i isto tako snižavaju krvni tlak inhibicijom angiotenzin-konvertaza enzima.
Compound 54 A compound according to claim 1, wherein the compound is selected from a group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je spoj izabran iz skupine koju čine. [image] [image]
Id. No. 10. The pharmaceutical formulation of claims 1 to 13, wherein light chain of the Abeta antibody comprises the amino acid sequence of Seq. 
Farmaceutska formulacija prema zahtjevima od 1 do 13, naznačena time, da slabi lanac od Abeta-protutijela sadrži aminokiselinsku sekvencu od SEQ ID NO:11.
With reference to Figure 1, mixing member 1 extends coaxially with a longitudinal axis A coinciding, in use, with the longitudinal axis of symmetry (not shown) of bowl 2, and comprises two supporting hubs 3 coaxial with longitudinal axis A and a predetermined distance apart; and a number of longitudinal blades 4, which project from one supporting hub 3 to the other, while remaining substantially parallel to longitudinal axis A of mixing member 1, and are spaced angularly about longitudinal axis A to form a "squirrel cage" structure bounded laterally by a cylindrical reference surface, which is coaxial with longitudinal axis A of mixing member 1, and has a radius of curvature smaller than the radius of curvature R0 of bowl 2, to permit insertion and rotation of mixing member 1 inside bowl 2. 
Referirajući se na Sliku 1, članak za miješanje 1 se koaksijalno proteže s uzdužnom osi A, koincidirajući u uporabi s uzdužnom osi simetrije (nije prikazana) od zdjele 2 1 sastoji se od dvije potporne glavine 3, koaksijalne s uzdužnom osi A i odijeljene na predodređenoj udaljenosti; i od određenog broja uzdužnih lopatica 4, koje strše iz jedne potporne glavine 3 prema drugoj, ostajući u biti paralelnim prema uzdužnoj osi A članka za miješanje 1 i kutno su razmaknute oko uzdužne osi A da formiraju strukturu "krletke za vjevericu" ograničenu bočnom cilindričnom referentnom plohom koja je koaksijalna s uzdužnom osi A članka za miješanje 1, i ima radijus zakrivljenosti manji od radijusa zakrivljenosti Roy zdjele 2 da dopusti umetanje i rotaciju članka za miješanje 1 unutar zdjele 2.
Compound (I) is preferably a crystal. 
Postupak proizvodnje spoja formule (I):
The process of embodiment A, wherein the aqueous compositions provided to an extruder, and the kneading and denaturing steps (b) and (c) are conducted in the extruder. 
Postupak sukladno patentnom zahtjevu 1, naznačen time, da se vodeni pripravci koji se dobivaju na ekstruder, i koraci (b) i (c) gnječenja i denaturacije se provode u ekstruderu.
The system according to claim 1, wherein, in at least one position along a blade of each of said use and change keys, a side surface of the use key is in a different position from a side surface of the change key. 
Sustav prema patentnom zahtjevu 1. ili 2. 1li 3., kod kojeg je bočna površina (13) ključa smještena u različitom položaju od bočne površine (15) ključa za promjenu.
Oral pharmaceutical dosage form according to claim 1, wherein the dosage form releases substantially all of buprenorphine or said pharmaceutically acceptable salt within less than 1 minute, and preferably within less than 30 seconds after oral, preferably sublingual, application of the dosage form. 
Oralni farmaceutski dozirni oblik prema zahtjevu 1, gdje dozirni oblik oslobađa u biti sav buprenorfin ili njegovu farmaceutski prihvatljivu sol za manje od 1 minute, i poželjno za manje od 30 sekundi nakon oralne, poželjno sublingvalne, primjene dozirnog oblika.
Here the term “natural” is used to indicate that such a pyrazine derivative is obtained from a natural source, i.e. 
Ovdje se termin "prirodno" upotrebljava da bi označio da je takav derivat pirazina dobiven iz prirodnog izvora, tj.
The designation of substituent X as chloro, fluoro or bromo means that both substituents X have the same meanings. 
(5), pri čemu jo Ri; difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te
The alkaline phosphatase of any one of claims 1 to 3, wherein the sALP comprises amino acid residues 23-508 of SEQ ID NO: 15, preferably wherein the sALP consists of amino acid residues 23-512 of SEQ ID NO: 15, or 
Alkalna fosfataza prema bilo kojem zahtjevu od 1 do 3, naznačena time da a) sALP sadrži aminokiselinske ostatke 23-508 iz SEQ ID NO: 15, poželjno pri čemu sALP sadrži aminokiselinske ostatke 23-512 iz SEQ ID NO: 15, ili b) sALP sadrži aminokiselinske ostatke 23-508 iz SEQ ID NO: 18, poželjno pri čemu sALP sadrži aminokiselinske ostatke 23-512 iz SEQ ID NO: 18, ili
iii) one or more pharmaceutically acceptable carriers. 
< a ili njegova farmaceutski prihvatljiva sol.
incorporating into a paracetamol solution glucose at a concentration between 0.5% m/v and 3.0% m/v to stabilize said solution, to which is further added a chelant and a buffering agent; 
Vodena otopina paracetamola za uporabu u perfuziji sukladno patentnom zahtjevu 1, naznačena time, da je glukoza nazočna u koncentraciji između 1.0% m/v i 3.0% m/v. 3.
This technology requires an expensive equipment from the viewpoint of solvent recovery and regeneration, its productivity is poor, and it has unfavourable characteristics considering environmental, health and fire protection. 
Ova tehnologija zahtijeva skupu opremu iz točke motrišta sakupljanja i obnavljanja otapala, produktivnost je slaba i karakteristike su nepovoljne glede zdravlja, zaštite okoliša i opasnosti od požara.
The oil-extracted product of indigo naturalis as claimed in Claim 6, wherein the oil is a vegetable oil selected from the group consisting of olive oil, cottonseed oil, sesame oil, sunflower seed oil, peanut oil, wheat germ oil, soybean oil, jojoba oil, evening primrose oil, coconut oil, palm oil, sweet almond oil, aloe oil, apricot kernel oil, avocado oil, borage oil, hemp seed oil, macadamia nut oil, rose hip oil, pecan oil, hazelnut oil, sasanqua oil, rice bran oil, shea butter, com oil, camellia oil, grape seed oil, canola oil, castor oil, and combinations thereof. 
Uljem ekstrahirani produkt prirodnog indiga u skladu s patentnim zahtjevom 4, naznačen time što je ulje biljno ulje, koje se bira iz skupine koju čine maslinovo ulje, pamučno ulje, sezamovo ulje, suncokretovo ulje, kikirikijevo ulje, ulje iz pšeničnih klica, sojino ulje, jojobino ulje, noćurkovo ulje, kokosovo ulje, palmino ulje, bademovo ulje, aloino ulje, mareličino ulje, avokadovo ulje, boražinovo ulje, konopljino ulje, makadamijino ulje, šipkovo ulje, ulje pekan oraha, lješnjakovo ulje, sasankvino ulje, ulje iz rižinih mekinja, karitejev maslac, kukuruzno ulje, ulje čajevca, grožđano ulje, kanolino ulje, ricinusovo ulje, te njihove kombinacije.
The crystal according to Claim 1, wherein the crystal has a crystal form A. 
. < Kristal prema zahtjevu 1, naznačen time što kristal ima kristalni oblik A. 3.
The isolated antigen binding protein of claim 1 comprising either: a light chain variable domain selected from the group consisting of: 
2. -Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, sadrži: a. varijabilnu domenu lakog lanca izabranu iz grupe koja sadrži: i.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
film coating the tablets from step (6). 
oblaganja filmom tableta iz koraka (7).
at least one pulley (34) assembled on sliders (27) of said driving modules (26) of said ropes (4). 
- < najmanje jedan koloturnik (34) montiran na kliznike (27) spomenutih pogonskih modula (26) spomenute užadi
In particular, the invention relates to such a beverage or foodstuff that contains at least 0.5 mg/kg preferably at least 1 mg/kg, more preferably at least 3 mg/kg and most preferably at least 10 mg/kg of pyrazine derivatives as defined herein before. 
Naročito, izum se odnosi na takvo piće ili prehrambeni proizvod, koji sadržava najmanje 0,5 mg/kg, poželjno najmanje 1 mg/kg, poželjnije najmanje 3 mg/kg i najpoželjnije najmanje 10 mg/kg derivata pirazina kao što je ovdje ranije definirano.
The retaining member may be shaped such that it engages a hole in the element. 
Član za držanje može biti oblikovan tako da on zahvaća rupu u elementu.
decreased expression of telomerase and one or more neural stem cell markers; 
- < smanjenu ekspresiju telomeraze i jednog ili više neuronskih markera matičnih stanica;
11, wherein the at least one substituent group is a hydroxyethyl group and the degree of substitution is selected such that a weight percent solids at a viscosity of 1000 cps and a temperature of 150 degrees Fahrenheit is in a range from 17 percent to 30 percent. 
Zidna gips ploča prema zahtjevu 2, naznačena time, da najmanje jedna eterska skupina je hidroksietilna skupina i da ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6*C (150*F) u rasponu od 17 do
a condition or of symptoms caused by tolerance development after exposure to 3-alpha-hydroxy-5-alpha/beta-steroids; 
stanja ili simptoma uzrokovanih razvijanjem tolerancije nakon izlaganja 3-alfa-hidroksi-5-alfa/beta-steroidima;
In an especially preferred embodiment, the fructosazine is selected from the group consisting of 2,5-deoxyfructosazine, 2,6-deoxyfructosazine and combinations thereof. 
U naročito poželjnom ostvarenju, fruktozazin je odabran iz skupine koju sačinjavaju 2,5-deoksifruktozazin, 2,6-deoksifruktozazin i njihove kombinacije.
A typical composition, obtained by the process of the invention, having an iodine index higher than 320, will have f.i. 
Tipični sastav, dobiven postupkom iz izuma, ima jodni broj viši od 320, će imati npr.
According to an embodiment, the second laser produced image is formed by laser engraving and the amount of the laser energy absorbed by the adjacent surface is at least 10 times higher than the amount of laser energy absorbed in the second image area. 
Sklop za identifikaciju prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je druga laserski producirana slika (21) uobličena laserskim utiskivanjem a količina laserske energije koju apsorbira susjedna površina (13, 14) je barem 10 puta veća od količine laserske energije apsorbirane u drugom slikovnom području
colloidal silicon dioxide, magnesium stearate, talc and starch. 
koloidni silicijev dioksid, magnezijev stearat, talk i škrob.
the proximal end of the second fragment is located within a second repeat portion; and wherein the first fragment and the second fragment are separated by less than or exactly 5 amino acids in the primary structure, wherein the polypeptide elicits antibodies that neutralise toxin A and toxin B and wherein the first repeat portion and the second repeat portion have greater than 50% sequence identity to one another. 
drugi fragment ima drugi proksimalni kraj; i gdje je prvi proksimalni kraj unutar kratkog ponavljanja i drugi proksimalni kraj je unutar kratkog ponavljanja; i gdje su prvi fragment i drugi fragment jedan uz drugog, te gdje polipeptid izaziva protutijela koja neutraliziraju toksin A i toksin B.
The method of clause 42, wherein solvent system comprises one or more organic solvents selected from 2-ethoxyethanol, ethyleneglycol, methanol, 2-methoxyethanol, 1-butanol, 2-butanol, 3-methyl-1-butanol, 2-methyl-1-propanol, ethanol, 1-pentanol, 1-propanol, 2-propanol, methylbutyl ketone, acetone, methylethyl ketone, methylisobutyl ketone, butyl acetate, isobutyl acetate, isopropyl acetate, methyl acetate, ethyl acetate, propyl acetate, pyridine, toluene, xylene, or any combination thereof. The method of clause 42, wherein solvent system comprises one or more organic solvents selected from acetone, n-propanol, isopropanol, iso-butylacetate, acetic acid, or any combination thereof. 
metoksietanola, 1-butanola, 2-butanola, 3-metil-1-butanola, 2-metil-1-propanola, etanola, 1-pentanola, 1- propanola, 2-propanola, metil-butil-ketona, acetona, metil-etil-ketona, metil-izobutil-ketona, butil-acetata, izobutilacetata, izopropil-acetata, metil-acetata, etil-acetata, propil-acetata, piridina, toluena, ksilena, ili bilo koje njihove kombinacije; ili gdje sustav otapala sadrži jedno ili više organskih otapala koja se bira između acetona, n-propanola, izopropanola, iso-butil-acetata, octene kiseline, ili bilo koje njihove kombinacije; ili gdje sustav otapala sadrži jedno ili više organskih otapala koja se bira između acetona ili izopropanola.
The pharmaceutical composition according to claim 7, comprising the compound of formula I shown below 
PATENTNI ZAHTJEVI 1. Farmaceutski sastav, naznačen time, da obuhvaća: a) spoj formule I
optionally the resulting blend is being sieved, the second part of the glidant chosen from a group comprising: stearic acid, magnesium stearate, glyceryl behenate, sodium stearyl fumarate is added and blended from 1 to 15 minutes. The process according to claim 11, in which the obtained blend is being tabletted by the direct compression process. 
€) opcionalno se dobivena smjesa prosije, drugi dio sredstva za podmazivanje odabran iz grupe koja obuhvaća: stearinsku kiselinu, magnezijev stearat, gliceril behenat, natrijev stearil fumarat se dodaje i miješa od 1 do 15 minuta; f) dobivena smjesa se oblikuje u tablete putem postupka direktne kompresije.
The transdermal therapeutic system according to claim 17 or 18, wherein the estrogen is Ethinylestradiol. 
Transdermalni terapeutski sustav u skladu sa zahtjevom 17 ili 18, naznačen time, da estrogen je Ftinilestradiol.
A CAP dependent endonuclease inhibitor according to any one of claims 1 to 7, wherein R3 is hydrogen, lower alkyl optionally substituted by substituent group A, lower alkenyl optionally substituted by substituent group A, lower alkynyl optionally substituted by substituent group A, carbocyclic group optionally substituted by substituent group A, carbocycle lower alkyl optionally substituted by substituent group A, carbocycleoxy lower alkyl optionally substituted by substituent group A, heterocycle lower alkyl optionally substituted by substituent group A, 
R> je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkinil prema potrebi supstituiran sa supstituentskom skupinom A, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom A, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, karbocikloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom A,
A compound according to claim 1 wherein at least one of m and r is 1, and wherein preferably the sum m+r is also 1. 
Spoj u skladu sa patentnim zahtjevom 1 naznačen time, da barem jedno od m i r je 1.
A method of treating chronic inflammation, allergies, contact dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, graft versus host disease, Alzheimer's disease, asthma, chronic kidney disease, sepsis, autoimmune myocarditis and systemic lupus erythematosus, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 1 . 
Spojevi prema prema bilo kojem od zahtjeva 1 do 14, naznačeni time, da se upotrebljavaju u liječenju kroničnog zapaljenja, alergija, kontaktnog dermatitisa, psorijaze, reumatoidnog artritisa, multiple skleroze, dijabetesa tipa 1, upalne bolesti crijeva, sindroma Guillain-Barre, Crohnove bolesti, ulcerativnog kolitisa, bolesti zbog reakcije usadka protiv stanice domaćina, Alzheimerove bolesti, astme, kroničnog oboljenja bubrega, sepse, autoimunog miokarditisa 1 eritematoze sistemskog lupusa.
R10a and R10b taken together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl; and is selected from the group consisting of hydrogen and alkylsulfonyl; or 
Ri R19 rje lili 2; uzeti zajedno s atomom ugljika za koji su pričvršćeni tvore 3- do 6- člani cikloalkil; ili njena farmaceutski prihvatljiva sol, ili njen solvat.
An antibody drug conjugate as defined in one of claims 1 to 18 for use in the treatment of cancer in a subject. 
Konjugat antitijela 1 lijeka definiran prema jednom od patentnih zahtjeva 1 do 18 za uporabu u liječenju raka u subjektu.
wherein the outer guide wall (163) is disposed at a peripheral edge of the first axial end of the cable spool (37, 137). 
Postupak izvlačenja optičkog kabela odmotavanjem (22, 122) iz kutije sa optičkim kabelom prema Zahtjevu 1, gdje završni modul (45, 149) sadrži veći broj kliznih adapterskih modula.
X1aa, X1ba, X1ca, and X1da are identical or different and are CR9a (wherein R9a is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group or an optionally substituted aryl group) or a nitrogen atom; 
aa, X1ba, X1ca i X1da su isti ili različiti te su CR9a (pri čemu je R9a atom vodika, atom halogena, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina ili po izboru supstituirana arilna skupina) ili atom dušika;
The method of claim 15, wherein the amount of budesonide administered is from about 0.01 mg to about 20 mg. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1 koja sadrži od 0.01 mg do 20 mg budezonida.
Ar1 is C6-10 aryl or 5- to 10-membered heteroaryl, wherein the aryl and heteroaryl groups are each optionally substituted with one to three substituents selected from Rb, Rc, and Rd; 
Ar1 je C6-10 aril ili 5- do 10-člani heteroaril, pri čemu su skupine aril i heteroaril svaka po izboru supstituirane s jednim do tri supstituenta odabrana od Rb, Rc, i Rd;
Pharmaceutical composition according to claim 7 containing dimethylfumarate at a dose range of 60 mg to 250 mg and teriflunomide at a dose range of 0.5 mg to 3 mg. 
Kombinacija za uporabu prema zahtjevu 16. naznačena time što sadrži dimetilfumarat u rasponu doze od 60 mg do 250 mg i teriflunomid u rasponu doze od 0,5 mg do 3 mg ili fingolimod u rasponu doze od 0,025 mg do 0,20 mg.
The antibody-drug-conjugate of any of the preceding claims for use as a medicament. 
Konjugat lijeka i antitijela iz bilo kojeg od prethodnih patentnih zahtjeva za upotrebu kao lijek.